Multiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in the fast-growing field.
The fresh drive for bispecifics has quickened pace over the past few months on the back of a huge licensing...